The slow uptake of biosimilars in some markets may stem in part from patients and healthcare providers being subjected at times to “misleading, incomplete, out-of-context, and at times incorrect information about biosimilars,” executives from Sandoz Inc. and Boehringer Ingelheim GmbH argue in an opinion piece for the biologic therapies journal, BioDrugs.
Authored by by Sandoz’s executive director for Scientific Affairs, Hillel Cohen, and edited by Dorothy McCabe, the German firm’s executive director for specialty medicines, including biosimilars, the article asserts there are “several different types of disparagement and misinformation directed against biosimilars, individually and